The Self-Medication Manufacturers’ Association of South Africa (SMASA) was formally formed in mid-1999 to ensure this important sector of the healthcare industry has a voice in discussions, which affect the health market place in South Africa.
SMASA consists of various member companies in the pharmaceutical and broader healthcare industry. The member companies elect representatives to an Executive Committee (EXCO), which meets regularly to discuss and take action on matters relevant to the industry. Kym Hampton is the current Chairperson of SMASA and Nicola Brink is the Executive Director of the Association.
The objectives of the Association are inter-alia to play a role in the promotion and support of legislative matters; to interact with government, other industry associations and statutory councils.
The Association promotes and protects the interests of the Members of the Association, encouraging co-operation between members and dealing with matters that may affect the common interests of members.
SMASA confers with the Government, and its departments, as well as other interested bodies and parties; and collects and disseminates information likely to be of use to members. Over the years SMASA has been involved in commenting on the Medicines Bill, the draft Benchmarking Regulations, the proposed Logistic Fees and Complementary Medicines and Medical Devices Regulations, Food Regulations, the scheduling of medicines and various guidelines for the registration of medicines, etc. In addition various meetings have been held with the Regulatory Authority on the ban of Advertising of Schedule 2 medicines, which remains an ongoing project. We are currently working with the WSMI (World Self-medication Industry) Task Group looking at the restrictions on the advertising of OTC medicines globally. SMASA continue to serve on various industry initiatives and hold two seats on the Industry Task Group (ITG). Other matters close to our heart are the Schedule 0 Exemption and the Consumer Protection Act.
SMASA has embarked on a PR campaign to promote responsible self-care and self-medication. This project each year culminates into International Self-care Day 24/7 on 24 July every year. SMASA is very active in other industry initiatives an example of which is the Codeine Care project which is a project introduced to mitigate the abuse and misuse of codiene and to accurately screen and control the sale of codeine containing OTC products in South Africa at a pharmacy level.
The Association has a Technical Committee looking at technical matters, including guidelines and policy matters from the Medicines Control Council and legislation.
SMASA is a member of the Marketing Code Authority and serves on the technical committee known as CTAC. SMASA has a seat on the board of the Marketing Code Association. In addition to the Association’s involvement in the compilation of Part A of the Code and the proposed Guideline for the Authority, we compiled Part B of the Code with the relevant Guidance Document for the Self-Medication Industry. In addition Nicola Brink serves as panelists to the Marketing Code on SMASA’s behalf.
SMASA is a member of the World Self-Medication Industry (WSMI) and benefits greatly from their activities. WSMI focuses on three core activities – support to emerging markets, and development of the ‘evidence base’ for non-prescription medicines, and collaborating with multi-lateral organizations.
Manufacturers and other organizations engaged in the self-medication manufacturing industry within South Africa are eligible for membership of the Association. Current members include:
Provision is made for a category called Associate Members who can be a person or a company involved in the supply chain between the manufacturer and the consumer or end-user of self-medication or industry consultants.
Associate members include:
Contact
Self-Medication Manufacturers Association of South Africa
Postal Address: P O Box 651573, Benmore, 2010
Tel: +27(0) 82 410 5859
Email: nicola@smasa.cc
Website: www.smasa.cc
Executive Director: Nicola Brink • Chairperson: Kym Hampton
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status.…
Writing in the February 2024 edition of the DIA Global Forum magazine, Verena Pfaffinger and Ilona Baraniak-Lang of PharmaLex examine how the drug shortages seen in the global south during…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
See our Cookie Privacy Policy Here
